CYTOSINE ARABINOSIDE FOR MULTIFOCAL LEUKOENCEPHALOPATHY IN HIV INFECTION
$273,591R01FY2000NSNIH
Washington University, Saint Louis MO
Investigators
Linked publications & trials
Paper 25678143Paper 25377444Paper 24297499Paper 23690260Paper 23565581Paper 23503447Paper 23335197Paper 23269596Paper 22806348Paper 22013244Paper 21900636Paper 21877204Paper 21777829Paper 21533012Paper 21423790Paper 21423788Paper 21330902Paper 21181521Paper 21124201Paper 20537129Paper 20400411Paper 20194920Paper 20133265Paper 19907013Paper 19890073Paper 19622045Paper 19424052Paper 19200173Paper 19139369Paper 18957181Paper 18791114Paper 18753934Paper 18447615Paper 17653259Paper 17652642Paper 17562831Paper 17454450Paper 17215331Paper 17156301Paper 17047492Paper 16847405Paper 16769940Paper 16392089Paper 16333071Paper 16287792Paper 16267764Paper 16103764Paper 15883332Paper 15779034Paper 15622315Paper 12707851Paper 12451199Paper 12218391Paper 11834952Paper 11781415Paper 11684949Paper 11591856Paper 10720278
Abstract
This Project will evaluate the effectiveness of cytosine arabinoside for treatment of biopsy proven progressive multifocal leukoencephalopathy in subjects with human immunodeficiency virus infection. A three arm study comparing best possible anti-retroviral therapy with either intravenous ARA-C therapy administered through an Ommaya reservoir. Twenty patients will be randomized to each arm of the study. The primary endpoint is death within 24 weeks. Secondary end points will be neurologic deterioration as indicated by neurologic examination and deterioration in Karnofsky Performance Scores.
View original record on NIH RePORTER →